INTRAVITREAL BEVACIZUMAB VERSUS COMBINED INTRAVITREAL BEVACIZUMAB AND TRIAMCINOLONE FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Six-Month Results of a Randomized Clinical Trial

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Retina

• Publication date

  2011-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/IAE.0b013e31820d58f2PMID 21555967
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intravitreal Bevacizumab Combined With Intravitreal Triamcinolone for Therapy-Resistant Exudative Age-Related Macular Degeneration

  2010cited by this paper
• Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration

  2009cited by this paper
• Combined Intravitreal Pharmacosurgery in Patients with Occult Choroidal Neovascularization Secondary to Wet Age-Related Macular Degeneration

  2009cited by this paper
• A prospective study on intravitreal bevacizumab (Avastin®) for neovascular age‐related macular degeneration of different durations

  2008cited by this paper
• Intravitreal Bevacizumab versus Combined Bevacizumab and Triamcinolone Acetonide for Neovascular Age-Related Macular Degeneration

  2008cited by this paper
• 12-MONTH RETROSPECTIVE STUDY AND REVIEW OF PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION

  2008influential reference
• Intravitreal Bevacizumab and Triamcinolone Acetonide Combination Therapy for Exudative Neovascular Age-Related Macular Degeneration: Short-Term Optical Coherence Tomography Results

  2008cited by this paper
• Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results

  2008cited by this paper
• Implications of bevacizumab on vascular endothelial growth factor and endostatin in human choroidal neovascularisation

  2008cited by this paper
• Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial

  2008cited by this paper
• A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

  2008cited by this paper
• Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.

  2008cited by this paper
• Early effects of triamcinolone on vascular endothelial growth factor and endostatin in human choroidal neovascularization.

  2008cited by this paper
• STANDARDIZED VISUAL ACUITY RESULTS ASSOCIATED WITH PRIMARY VERSUS SECONDARY BEVACIZUMAB (AVASTIN) TREATMENT FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION

  2007cited by this paper
• Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.

  2007cited by this paper
• RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

  2007cited by this paper
• INTRAVITREAL BEVACIZUMAB FOR PREVIOUSLY TREATED CHOROIDAL NEOVASCULARIZATION FROM AGE-RELATED MACULAR DEGENERATION

  2007cited by this paper
• Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type.

  2007cited by this paper
• Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

  2006cited by this paper
• INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION

  2006cited by this paper
• VISUAL IMPROVEMENT FOLLOWING INTRAVITREAL BEVACIZUMAB (AVASTIN) IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION

  2006influential reference
• Intravitreal triamcinolone acetonide for exudative age related macular degeneration

  2003cited by this paper
• Statistical analysis of correlated data using generalized estimating equations: an orientation.

  2003cited by this paper
• A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results.

  2003cited by this paper
• INTRAVITREAL TRIAMCINOLONE ACETONIDE IN EXUDATIVE AGE‐RELATED MACULAR DEGENERATION

  2000cited by this paper
• The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes.

  1999influential reference
• Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells.

  1998cited by this paper
• The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group.

  1993cited by this paper
• The Lens Opacities Classification System III

  1993cited by this paper

• The Role of Inflammation in Age-Related Macular Degeneration.

  2025cites this paper
• Simultaneous Intravitreal Steroid and Anti-VEGF Therapy for Monotherapy-Resistant Chronic Wet Age-Related Macular Degeneration.

  2024cites this paper
• Clinical efficacy of intravitreal corticoid as an adjunctive therapy to anti-VEGF treatment of neovascular age-related macular degeneration: a Meta-analysis.

  2021cites this paper
• Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration

  2021cites this paper
• Berichten RCT-Publikationen zur Versorgung von AMD-Patienten Baseline-Daten zum eingebrachten Patientengut mit Blick auf die Generalisierbarkeit des Studiendesigns?

  2019cites this paper
• Intravitreal Bevacizumab with or without Triamcinolone for Wet Age-related Macular Degeneration: Twelve-month Results of a Prospective, Randomized Investigation

  2018influential citation
• Simultaneous Dexamethasone Intravitreal Implant and Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration Resistant to Anti-VEGF Monotherapy

  2017cites this paper
• Pharmacologic Treatment of Wet Type Age-related Macular Degeneration; Current and Evolving Therapies.

  2017cites this paper
• Comparison of Combined Bevacizumab plus Dexamethasone Vs. Ranibizumab Monotherapy as First-Line Therapy in Patients with Treatment Naive Neovascular Age-Related Macular Degeneration in Real-Life Clinical Practice: A Retrospective Case-Series Analysis

  2017cites this paper
• Analyzing Relative Blood Flow Speeds in Choroidal Neovascularization Using Variable Interscan Time Analysis OCT Angiography.

  2017cites this paper
• Corticosteroids: Triamcinolone, Dexamethasone and Fluocinolone.

  2016cites this paper
• Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies

  2016cites this paper
• Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial

  2015cites this paper
• Inflammatory Mechanisms of Age-related Macular Degeneration

  2015cites this paper
• Sustained release of triamcinolone acetonide from an episcleral plaque of multilayered poly-ε-caprolactone matrix.

  2014cites this paper
• Photodynamic Therapy and Intravitreal Bevacizumab with Versus without Triamcinolone for Neovascular Age-related Macular Degeneration; a Randomized Clinical Trial

  2014cites this paper
• Intraocular concentrations of cytokines and chemokines in rhegmatogenous retinal detachment and the effect of intravitreal triamcinolone acetonide.

  2013cites this paper
• [Off-label prescribing: scientific analysis taking the use of bevacizumab in ophthalmology as an example].

  2013cites this paper
• Immunology of age-related macular degeneration

  2013cites this paper
• Pharmacogenomics in ophthalmology

  2013cites this paper
• Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration

  2013cites this paper
• Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration

  2013cites this paper
• Pharmacogenetics and Age-Related Macular Degeneration

  2011cites this paper